Genentech reports positive results from Phase III CLEOPATRA study
The Phase III double-blind study randomised 808 people with HER2-positive mBC, which recurred after prior therapy in the adjuvant or neoadjuvant setting. Genentech global product development head and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.